Rimma Goldberg

Rimma Goldberg is an Associate Professor at Monash University’s School of Clinical Sciences and a gastroenterologist at Monash Health. She specializes in inflammatory bowel disease (IBD), focusing on developing novel cell-based therapies and advancing understanding of adaptive/innate immunity roles in IBD pathogenesis. Her work bridges clinical practice and research, with a particular emphasis on pregnancy-related IBD management and regenerative medicine approaches.

• Affiliations: Monash Health (Clinical Practice), School of Clinical Sciences (Research)
• Education: PhD in Immunology/Mucosal Biology (King’s College London, 2019), MBBS & BMedSci (University of Melbourne, 2007)

Her research interests include regulatory T cell therapies, IBD immunopathology, and translational strategies to improve patient outcomes. Key projects include Phase 1 clinical trials for autologous Treg-based therapies and collaborations on gastrointestinal fibrosis treatments.

Recent articles highlight her contributions to understanding maternal IBD drug exposure effects on infants, optimizing thiopurine dosing in pregnancy, and advancing Treg cell therapy efficacy. She has received prestigious awards including the British Society of Gastroenterology’s Best Scientific Abstract Award and the Society of Mucosal Immunology’s Rising Stars honor.

Dr. Goldberg leads multiple grants, including projects on gut-specific ALK5 inhibitors and next-generation glucocorticoid therapies. She collaborates internationally and serves on industry advisory boards (e.g., Janssen).

Her lab focuses on regenerative therapies and immune modulation, with future work targeting personalized IBD treatments and maternal-fetal immune interactions.